TEGSEDI® REMS Program Overview
(Risk Evaluation and Mitigation Strategy)

This overview describes the requirements of the TEGSEDI (inotersen) REMS and the responsibilities of prescribers, pharmacies and patients.

If you have any questions regarding the TEGSEDI REMS, please visit www.TEGSEDiREMS.com or call 1-844-4TEGREMS (1-844-483-4736).

Reference ID: 4961392
What is the TEGSEDI REMS?

- A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential risks associated with a drug, and is required by the Food and Drug Administration (FDA) to ensure the benefits of the drug outweigh its risks.
- Because of the risk of serious bleeding due to severe thrombocytopenia and the risk of glomerulonephritis, TEGSEDI is available only under a restricted program called the TEGSEDI REMS.

TEGSEDI may cause serious bleeding due to severe thrombocytopenia. The signs and symptoms of thrombocytopenia may include:
- Unusual bruising or a rash of tiny reddish-purple spots, often on the lower legs
- Bleeding from skin cuts that does not stop or oozes
- Bleeding from the gums or nose
- Blood in urine or stools
- Bleeding into the whites of eyes
- Sudden severe headaches or neck stiffness
- Vomiting blood or coughing up blood
- Abnormal or heavy menstrual periods

TEGSEDI may cause glomerulonephritis. The signs and symptoms of glomerulonephritis include:
- Puffiness or swelling in face, feet or hands
- New onset or worsening shortness of breath and coughing
- Blood in urine or brown urine
- Foamy urine (proteinuria)
- Passing less urine than usual
How does the TEGSEDI REMS work?

Before Prescribing/Dispensing TEGSEDI

Prescriber Certification

Before Starting TEGSEDI for each Patient

Counsel the patient on the risks of serious bleeding with thrombocytopenia and glomerulonephritis

Assess the patient’s platelet count and kidney function

Enroll Patient

While on TEGSEDI Treatment for each Patient

Assess Patient’s platelet count and kidney function

Submit the Patient Status Forms as directed in the REMS requirements

Obtain authorization for each dispense by confirming Prescriber is certified and Patient is enrolled

Carry the Wallet Card with you at all times and inform your prescriber if you have symptoms of low platelet count or kidney inflammation

What are the Requirements of the TEGSEDI REMS?

- In order for patients to receive TEGSEDI, prescribers, pharmacies, and patients must comply with the requirements of the TEGSEDI REMS

To prescribe TEGSEDI:

1. Become certified by completing a one-time certification process
2. Assess the patient’s platelet count and kidney function
3. As you start patients on TEGSEDI, counsel and enroll them into the TEGSEDI REMS
4. Perform ongoing assessments of platelet counts and kidney function
5. Document and Submit a Patient Status Form during treatment at the time of treatment discontinuation and 8 weeks after treatment discontinuation

To dispense TEGSEDI*:

1. Designate an authorized representative, become certified, and recertify if there is a change in the authorized representative
2. Train staff and comply with REMS requirements
3. Before dispensing TEGSEDI, verify prescriber is certified and patient is authorized to receive TEGSEDI

To receive TEGSEDI:

1. Understand the risks associated with TEGSEDI
2. Enroll in the REMS by completing the Patient Enrollment Form with your healthcare provider
3. Get a blood test and a urine test prior to treatment, during treatment and after treatment discontinuation

*TEGSEDI is not available to all pharmacies. If you have any questions about the REMS or how to obtain TEGSEDI, call 1-844-483-4736.
Prescriber Requirements

Become Certified (One-time)

Before prescribing TEGSEDI:

1. Review the following educational materials on TEGSEDI to understand the risks of serious bleeding with severe thrombocytopenia and glomerulonephritis, and the TEGSEDI REMS:
   - Prescribing Information
   - Prescriber Training
   - REMS Program Overview (this document)
2. Complete and submit the following to become certified:
   - Prescriber Knowledge Assessment
   - Prescriber Enrollment Form
3. Once completed, the TEGSEDI REMS will notify you that you are certified to prescribe TEGSEDI

Enroll Patients

Before starting each patient on TEGSEDI:

1. Counsel your patient about the risks associated with TEGSEDI, including serious bleeding with severe thrombocytopenia and glomerulonephritis and share the resources below:
   - Patient Guide
   - Wallet Card
2. Assess the patient’s platelet count and kidney function for appropriateness of initiating treatment
3. Submit a completed Patient Enrollment Form to the TEGSEDI REMS. Provide a copy of the form to the patient

At All Times

Once your patient is on TEGSEDI:

1. Report any events of severe thrombocytopenia, serious bleeding with thrombocytopenia, and glomerulonephritis to the REMS Program
2. Assess the patient’s appropriateness for continuing treatment by monitoring their platelet count and kidney function
3. Submit the Patient Status Form during treatment, at the time of treatment discontinuation and at 8 weeks after treatment discontinuation
4. Inform the TEGSEDI REMS if a patient is no longer under your care or has discontinued TEGSEDI

*The REMS will send a reminder to the certified prescriber of record when the Patient Status Form is due.

Completed forms should be submitted to the TEGSEDI REMS online at www.TEGSEDIrems.com or via fax to 1-855-483-4736.

Pharmacy Requirements

Become Certified

Before Dispensing TEGSEDI:

1. Designate an authorized representative for the pharmacy to carry out the certification process. He or she will need to review the REMS Program Overview and will oversee implementation and ensure compliance with the TEGSEDI REMS requirements
2. Have the authorized representative complete and submit the Pharmacy Enrollment Form by fax
   - Once this step is completed, the TEGSEDI REMS will notify you that you are certified to dispense TEGSEDI
3. Have the authorized representative ensure that all relevant staff involved in dispensing TEGSEDI are trained on the TEGSEDI REMS requirements using the Program Overview, and that a record of the training is maintained by the pharmacy
4. Establish processes and procedures to dispense no more than a 30-day supply
5. Establish processes and procedures to report severe thrombocytopenia, serious bleeding with severe thrombocytopenia, and glomerulonephritis events to the REMS

Ensure Compliance with REMS Requirements

When Dispensing TEGSEDI:

1. Before dispensing TEGSEDI, verify that the prescriber is certified and the patient is authorized to receive TEGSEDI by accessing the TEGSEDI REMS Portal or by calling the TEGSEDI REMS
2. Report severe thrombocytopenia, serious bleeding with severe thrombocytopenia, and glomerulonephritis events to the REMS
3. Maintain records that all REMS processes and procedures are in place and are being followed
4. Recertify in the TEGSEDI REMS if a new authorized representative is designated by completing and submitting the Pharmacy Enrollment Form

TEGSEDI is not available to all pharmacies. If you have questions about the REMS or how to obtain TEGSEDI, call 1-844-483-4736.
Patient Requirements

Enroll and Get Blood and Urine Testing

Before starting TEGSEDI:

1. Discuss with your doctor and understand:
   - The risks associated with TEGSEDI, including serious bleeding and kidney inflammation
   - The need to complete the appropriate lab testing

2. Receive and read the:
   - Patient Guide
   - Wallet Card

3. Complete the Patient Enrollment Form with your doctor

Complete Ongoing Testing as Directed by Prescriber

After starting TEGSEDI:

1. Carry the Wallet Card with you at all times and Inform your healthcare provider about this treatment

2. Inform your healthcare provider if you have any signs and symptoms of low platelet count or kidney inflammation

3. Get the appropriate lab testing during treatment and after discontinuation

TEGSEDI REMS Resources

Before Prescribing/Dispensing TEGSEDI

- Prescribing Information
- Prescriber Training
- Program Overview
- Prescriber Knowledge Assessment
- Prescriber Enrollment Form
- Patient Enrollment Form

Before Starting TEGSEDI for each Patient

- Program Overview
- Pharmacy Enrollment Form

While on TEGSEDI Treatment, at treatment discontinuation and at 8-weeks post TEGSEDI Discontinuation

- Patient Status Form

TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Please see the Prescribing Information for more information.